Precision immuno-oncology in triple-negative breast cancer: from PD-L1 to multimodal biomarkers, ADC-ICI combinations, and global real-world integration.
The online reader was unable to display this document directly. This may occur if the repository host is temporarily unreachable, or if security restrictions (CORS) prevent embedded viewing.